EMA to relocate to Amsterdam, the Netherlands
- Details
- Category: EMA
The European Medicines Agency (EMA) will relocate to Amsterdam in the Netherlands. This decision was taken by the EU 27 Member States in the margins of the General Affairs Council (Art. 50). The Agency now has just over 16 months to prepare for the move and take up its operations in Amsterdam on 30 March 2019 at the latest.
FDA approves pill with sensor that digitally tracks if patients have ingested their medication
- Details
- Category: FDA
The U.S. Food and Drug Administration has approved the first drug in the U.S. with a digital ingestion tracking system. Abilify MyCite (aripiprazole tablets with sensor) has an ingestible sensor embedded in the pill that records that the medication was taken. The product is approved for the treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar I disorder and for use as an add-on treatment for depression in adults.
FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer
- Details
- Category: FDA
The U.S. Food and Drug Administration has expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose cancer cells have a specific genetic mutation known as BRAF V600. This is the first FDA-approved treatment for ECD.
FDA warns companies marketing unproven products, derived from marijuana, that claim to treat or cure cancer
- Details
- Category: FDA
As part of the U.S. Food and Drug Administration's ongoing efforts to protect consumers from health fraud, the agency today issued warning letters to four companies illegally selling products online that claim to prevent, diagnose, treat, or cure cancer without evidence to support these outcomes. Selling these unapproved products with unsubstantiated therapeutic claims is not only a violation of the Federal Food, Drug and Cosmetic Act, but also can put patients at risk as these products have not been proven to be safe or effective.
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma
- Details
- Category: FDA
The U.S. Food and Drug Administration approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL).
FDA awards 15 grants for clinical trials to stimulate product development for rare diseases
- Details
- Category: FDA
The U.S. Food and Drug Administration today announced that it has awarded 15 new clinical trial research grants totaling more than $22 million over the next four years to boost the development of products for patients with rare diseases. These new grants were awarded to principal investigators from academia and industry across the country.
FDA awards six grants for natural history studies in rare diseases
- Details
- Category: FDA
The U.S. Food and Drug Administration today announced it has awarded six new research grants for natural history studies in rare diseases. The aim of the research is to inform medical product development by better understanding how specific rare diseases progress over time.
More Pharma News ...
- FDA improves access to reports of adverse drug reactions
- FDA conducts major global operation to protect consumers from potentially dangerous prescription drugs sold online
- FDA approves first biosimilar for the treatment of cancer
- FDA approves Mylotarg for treatment of acute myeloid leukemia
- FDA approval brings first gene therapy to the United States
- FDA approves first U.S. treatment for Chagas disease
- FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia